It has shown anti-tumor efficacy in CRC models, including HER2 mutations conferring trastuzumab resistance, suggesting a synergistic effect when combined with trastuzumab in chemo-refractory patients [23,46]. Here, ERBB2 is linked to colorectal carcinoma.